Literature DB >> 8758245

Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast.

T Perin1, V Canzonieri, S Massarut, E Bidoli, C Rossi, M Roncadin, A Carbone.   

Abstract

In order to obtain prognostic clinicopathological information, 49 cases of pure ductal carcinoma in situ of the breast (DCIS), were evaluated for the immunohistochemical expression of potential predictor markers including c-erbB-2 oncogene product, p53 protein, oestrogen (ER) and progesterone (PR) receptors, oestrogen-regulated proteins pS2 and cathepsin-D (cath-D), CD44 protein and 67-kDa laminin receptor (MLuC5). Immunohistochemical findings were compared with conventional pathological parameters, clinical findings, and the clinical outcome of the patients. When markers were matched to each other, statistical analyses provided a significant positive correlation between c-erbB-2 overexpression and p53 positivity (P < 0.01) and between ER and PR (P < 0.01), ER, PR and pS2 (P < 0.01), pS2 and MLuC5 (P < 0.05). Significant negative correlations between c-erbB-2 overexpression and ER (P < 0.05), PR (P < 0.01) and pS2 (P < 0.01) positivity was also observed. Data on the relationship between marker status and pathological findings revealed a significant positive trend between c-erbB-2, p53, and increased grade values (P < 0.05) and opposite results with PR receptor expression (P < 0.01). c-erbB-2 overexpression was further significantly associated with comedotype carcinoma (P < 0.05) and distribution of disease in confluent neoplastic ducts (P < 0.01). Although no statistically significant correlation among biological markers expression, clinical findings and outcome was demonstrated, overall this study indicates that tumour cells from a subset of DCIS, which includes comedotype carcinoma, express significantly unfavourable prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758245     DOI: 10.1016/0959-8049(96)00037-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Authors:  Kalliopi P Siziopikou; Stewart J Anderson; Melody A Cobleigh; Thomas B Julian; Douglas W Arthur; Ping Zheng; Eleftherios P Mamounas; Eduardo R Pajon; Robert J Behrens; Janice F Eakle; Nick C Leasure; James N Atkins; Jonathan A Polikoff; Thomas E Seay; Worta J McCaskill-Stevens; Rachel Rabinovitch; Joseph P Costantino; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2013-11-08       Impact factor: 4.872

2.  Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

Authors:  Li Ding; Zijin Zhang; Yan Xu; Yongqiang Zhang
Journal:  Bioengineered       Date:  2017-01-11       Impact factor: 3.269

3.  p53 mutations and expression in breast carcinoma in situ.

Authors:  J Lukas; N Niu; M F Press
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.

Authors:  Jing Lu; Hua Guo; Warapen Treekitkarnmongkol; Ping Li; Jian Zhang; Bin Shi; Chen Ling; Xiaoyan Zhou; Tongzhen Chen; Paul J Chiao; Xinhua Feng; Victoria L Seewaldt; William J Muller; Aysegul Sahin; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

5.  Biological Markers Predictive of Invasive Recurrence in DCIS.

Authors:  Sharon Nofech-Mozes; Jacqueline Spayne; Eileen Rakovitch; Harriette J Kahn; Arun Seth; Jean-Phillippe Pignol; Lavina Lickley; Lawrence Paszat; Wedad Hanna
Journal:  Clin Med Oncol       Date:  2008-01-22

6.  Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.

Authors:  Melody A Cobleigh; Stewart J Anderson; Kalliopi P Siziopikou; Douglas W Arthur; Rachel Rabinovitch; Thomas B Julian; David S Parda; Samantha A Seaward; Dennis L Carter; Janice A Lyons; Melissa S Dillmon; Gustav C Magrinat; Vivek S Kavadi; Allison M Zibelli; Lavanya Tiriveedhi; Matthew L Hill; Marianne K Melnik; Sushil Beriwal; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2021-03-19       Impact factor: 50.717

7.  Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response.

Authors:  Blanca Murillo-Ortiz; Horacio Astudillo-De la Vega; Sebastian Castillo-Medina; J M Malacara; Luis Benitez-Bribiesca
Journal:  BMC Cancer       Date:  2006-08-15       Impact factor: 4.430

8.  Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

Authors:  N Bijker; J L Peterse; L Duchateau; E C Robanus-Maandag; C A Bosch; C Duval; S Pilotti; M J van de Vijver
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

9.  A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.

Authors:  Wenjing Zhou; Christine Johansson; Karin Jirström; Anita Ringberg; Carl Blomqvist; Rose-Marie Amini; Marie-Louise Fjallskog; Fredrik Wärnberg
Journal:  Int J Breast Cancer       Date:  2013-12-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.